Back to the Picasso trial for some perspective on Clover.

New Post Public Reply Private Reply Replies (1) Message Board
sherlock57
1,192
Back to the Picasso trial for some perspective on Clover. It bothers me that the prime and pair idea failed with maraviroc and Keytruda. As noted in a recent post, chemo was not used in Picasso until patients finished the combination therapy, as a salvage effort. So that is likely part of the picture. In effect, maraviroc does prime or sensitize the tumors—but to chemo, not the ICI. And the proof of that is the excellent Disease Control Rate of 70% in the salvage patients, along with a then-respectable Overall Survival figure of 9.8 months. But what else is going on? Why didn’t a CCR5 inhibitor that works in HIV not prime cancer to respond to Keytruda?

Turns out the answer is pretty simple—maraviroc does not raise PDL-1 in the tumors! At least that’s what AI tells me. Apparently this has everything to do with the short half-life of maraviroc in the body, which logs in at 10.5 hours. So receptor occupancy fluctuates during the day as the liver processes and removes the drug from circulation… so if you don’t take your twice-a-day pills right on schedule, or miss a dose, the tumor has windows of opportunity to exploit and resist.

They tried to work around this by upping the dose significantly, in conjunction with something called CYP3A4 Inducers. For HIV, typically taken along with CYP3A4 Inhibitors, the usual dose is 150mg twice a day, for a total of 300mg. If you are not taking any other drugs processed by the liver you can safely take 600mg a day, in split doses. In the Picasso trial they tried up to 2,400mg a day, in split doses. Yikes! Maraviroc is a drug that is hard on the liver, so they would have had to monitor patients closely, and reduce dosage as needed. More windows of opportunity for the tumor, especially in the liver.

Well, it all makes sense now. Leronlimab is not only superior to maraviroc in terms of occupying the receptor exquisitely and competitively, but it’s long half-life means there are no gaps in coverage for a brain-fogged patient who gets confused about the dosing schedule. I was concerned that there might be some reason the prime and pair idea with leronlimab and an ICI might not work as effectively in mCRC as it did in TNBC, basically because maraviroc didn’t work in the Picasso trial. Now it is still an open question, in my mind at least, as to the level of effectiveness the LL/ICI pairing will have in various cancers… because there is no data yet, and cancer can be both tricky and harsh. I’ll just say, it would be unrealistic to expect, extrapolating from the 5 for 5 in TNBC, that we would cure 1,000 out of 1,000… even in TNBC. We can always dream big… even if we are still early in the leronlimab story.

One final thought—we usually think of “prime and pair” with leronlimab in terms of ICIs, but it is clear that P and P works for chemo as well. The combo creates an anti-cancer cascade, if you will—LL primes the chemo to more effectively kill cancer, which stimulates the release of antigens for the immune system to process, recognize, and dispatch any remaining cancer cells. While Taz appears to be the perfect companion for leronlimab in CRC, Cytodyn might want to search for other chemotherapies that would work well in specific cancers. I am really excited to see if we get any Complete Responses in the 700mg arm… and I’m talking without Keytruda! Perhaps with curative resection? And further down the line, we’ll see if the triplet leads to CRs in first or second-line indications. Looks likely to me. I-Spy, anyone? Pre Spy? The Man From Uncle?

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 115

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 43

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
LAFC Turns Empty Seats Into an AI Test Case for Sports

Updated Category News Views 55

Empty seats are a lousy kind of inventory A vacant stadium seat is perishable inventory with the clock screaming at it. LAFC and AccelerAI have aimed their first co-developed AI project at that unglamorous but important problem: getting more ticket holders through the gate without simply hacking prices down at the last minute. That is a far more sensible use of artificial...

Continue Reading
USFM's Disko Deal Waits on Greenland Until March 2027

Updated Category News Views 123

A missing Greenland signature has turned USFM’s grand Disko plan into a calendar problem. Nothing more dramatic has been disclosed, but nothing less consequential should be assumed either. March 31 replaces a deadline that already failed USFM executed its share purchase agreement with 80 Mile PLC and Disko Exploration Limited on May 8, 2026. The proposed bargain is...

Continue Reading
Bank of America AML Claims Put Controls Under Fire

Updated Category News Views 77

A $1.2 billion compliance bill has a way of making investors stop pretending controls are boring. Moore Law PLLC is urging Bank of America shareholders to contact the firm over allegations tied to the bank's anti-money-laundering and Bank Secrecy Act systems. The notice follows what it describes as landmark October 13, 2026 enforcement actions by the Treasury Department's...

Continue Reading
Animal Parasite Market Growth Has a Resistance Catch

Updated Category News Views 114

Flea collars and cattle worms do not sound glamorous, yet this is exactly where durable animal-health revenue gets built. Wissen Research puts the global animal parasiticides market at $13.6 billion in 2026 and projects $18.6 billion by 2031, a 6.5% compound annual growth rate. That is respectable, not moonshot stuff, and frankly that is part of the appeal. Pet owners...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Bona's 2027 Floorcast Finds Wood and Trust Still Win

Updated Category News Views 147

Floors are turning into a long-game purchase again Gray flooring may be limping toward the exit, but the more important signal in Bona's 2027 Floorcast is that homeowners are thinking less like bargain hunters and more like custodians of an expensive asset. That is a useful read for anybody watching the home-improvement and maintenance landscape. People do not replace a...

Continue Reading
MassMedia's Two PRSA Wins Put Campaign Strategy in Focus

Updated Category News Views 100

A pair of trophies is nice; the underlying work matters more. MassMedia picked up two honors at the 2026 PRSA Las Vegas Valley Chapter Pinnacle Awards, presented October 28 at Siena Golf Club. One was a Pinnacle Award in Community Relations for its Safe Teen Driving work with Sam & Ash Injury Law. The other was an Award of Excellence in Reputation and Brand Management for...

Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 100

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading

Top 5 Most Recently Viewed Articles

Anivive's Lab Expansion: Driving Innovation in Veterinary Diagnostics

Updated Category News Views 130

Expanding Horizons in Veterinary Diagnostics Anivive is embarking on an exciting journey as it expands its state-of-the-art laboratory, a move that reflects the soaring demand for its specialized pathology services. This enhancement comes in response to the growing interest in veterinary diagnostics, particularly through its subsidiary, Vidium, known for its leadership in...

Continue Reading
Aurora Chen Joins PBGH as Vice President to Lead Advisory Services

Updated Category News Views 239

Aurora Chen Joins PBGH as Vice President of Advisory Services PBGH, a notable nonprofit coalition, has proudly announced the appointment of Aurora Chen as its Vice President of Advisory Services. Bringing a wealth of experience in the health care and employee benefits sector, Chen is set to lead efforts that expand and enhance the advisory services offered by PBGH. This...

Continue Reading
What Are the Pros and Cons of Using a Financial Planner?

Updated Category Personal Finance Views 654

Are you considering enlisting the help of a financial planner and aren’t sure if it's the right choice for you? Then you need to know about their pros and cons! Financial planners play a vital role in offering you support and guidance with tailor-made plans that help you meet your savings, retirement, or investment goals. We have outlined the pros and cons of a...

Continue Reading
Angel Oak Financial Strategies Trust Announces March 2025 Dividend

Updated Category News Views 113

Introduction to Angel Oak Financial Strategies Income Term Trust Angel Oak Financial Strategies Income Term Trust (FINS) has declared a monthly distribution that investors eagerly anticipate. The closed-end fund listed on the New York Stock Exchange is making headlines as it announces a distribution of $0.109 per share for March. Understanding the mechanics behind such...

Continue Reading
Investors Eye Value Stocks as Federal Reserve Makes Moves

Updated Category News Views 81

Exploring Value Stocks Amid Federal Adjustments Bank of America has underscored three key sectors that stand to gain from the Federal Reserve's unique dual approach of cutting interest rates while profits rise in corporate sectors. This 'rare double whammy of stimulus' could present a significant opportunity for savvy investors keen on value stocks. Key Sector Highlights...

Continue Reading